
On Tuesday, Biomarin Pharmaceutical Inc. (NASDAQ:BMRN) reported second-quarter adjusted earnings of $1.44, up 50% year over year, beating the consensus of 85 cents and sales of $825.41 million, up 16%, beating the consensus of $760.39 million.
The sales increase was driven by strong 20% year-over-year growth in Voxzogo revenue from new patients initiating therapy across all regions. Global Voxzogo revenue growth in the quarter was led by U.S. contributions, with most new patients starting in the 0-4 year age group.